Non-Invasive Prenatal Testing

Slides:



Advertisements
Similar presentations
NON – INVASIVE PRENATAL TESTING
Advertisements

Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Genetic Testing in Pregnancy
Prevention of Birth Defects An Overview of Primary and Secondary Strategies.
Non-invasive Prenatal Trisomy test Leon Liang BGI Health Europe A safe prenatal testing for fetal chromosomal aneuploidy.
Second-trimester maternal serum screening
About these slides Provided by the CAP as an aid to pathologists to facilitate discussion on the topic. Content has been reviewed by experts at the CAP,
Alzheimer disease Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated April 2015.
Chapter 2 Now That You’re Pregnant
Genetics and Primary Care
Non-Invasive Prenatal Testing (NIPT)
An Introduction to Prenatal Chromosomal Microarray Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated April 2015.
NON – INVASIVE PRENATAL TESTING
Prenatal diagnosis Dr Neda Bogari.
June C Carroll MD CCFP FCFP Sydney G Frankfort Chair in FM
Prenatal Genetic Testing for Chromosomal Anomalies By: Linda DeFranco.
Enhanced Prenatal Screening Program
Best Start - Prenatal Education Program Prenatal Care.
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
Pregnancy & Newborn Screening Developments
Max Brinsmead MB BS PhD November  Some 1- 2% of babies will have a major disability that dates from the prenatal period  Either  Chromosomal.
Contemporary Prenatal Diagnosis – The Clinician’s Perspective
New Follow-up Service Introduced by the California Prenatal Screening Program Non-Invasive Prenatal Testing (NIPT, NPT) NIPT: Non-invasive prenatal testing.
TEMPLATE DESIGN © Retrospective Analysis of Amniocentesis in UKMMC ZulidaR, MAJamil Universiti Putra Malaysia, UPM Serdang,
Direct-to-Consumer Genetic Testing Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated April 2014.
Changes in Chromosome Number
First Trimester Screening
Module One: Introduction to the California Prenatal Screening Program
An Ounce of Prevention  2000, 2005, 2011 The Curators of the University of Missouri Preconception Planning and Monitoring Fetal Health Twenty Questions.
MQlicker This session will utilise the mQlicker interactive audience program Questions will be presented and you will be able to respond electronically.
In the name of god First Trimester Screening Dr.M.Moradi.
Pregnancy diagnosis, Prenatal care & Genetic counseling Wei Jiang, M.D. Attending of Ob & Gyn Ob & Gyn Hospital, Fudan University 419 Fangxie Road, Shanghai.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
Prenatal screening for genetic disorders: best current practice and what’s around the corner June C Carroll MD CCFP FCFP Sydney G Frankfort Chair in FM.
Private pay, physician ordered genetic testing Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated November 2015.
Consanguinity Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated November 2015.
The Role of Prenatal screening as part of Routine Obstetric Care
Prenatal Chromosomal Microarray Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated November 2015.
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
Non-Invasive Prenatal Testing (NIPT)
Alzheimer disease Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated Dec 2014.
HIGHER HUMAN BIOLOGY Unit 2 Physiology and Health 1. Ante-natal Screening.
Module Five: Viewing Results in SIS. Introduction – Viewing Results Accurately communicating case interpretation to patients is one of the most important.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
Vancouver Division of Family Practice and Perinatal Services BC Prenatal Genetic Screening Program Present: Prenatal Genetic Screening Langley Division.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Non-invasive Prenatal Testing
Self-pay, expanded carrier screening Developed by Ms. Shawna Morrison, Dr. June Carroll, and Dr. Judith Allanson Last updated May 2016.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Prenatal Screening and Diagnosis. What is Prenatal Diagnosis?  In-utero detection of fetal anomalies General population risk is 3-5% for any birth defect.
a systematic review and meta-analysis
In The Name Of God. In The Name Of God Prenatal Diagnosis of Congenital Disorders Dr. Gita Hatamizadeh OBGYN- Infertility Fellowship Assisted professor.
UOG Journal Club: January 2016
Preimplantation Genetic Diagnosis (PGD)
DO NOT ORDER at any gestational age.
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
Introduction to prenatal diagnosis
Your unborn baby has been diagnosed with a heart problem
Prenatal testing.
Prenatal Screening for Genetic Conditions
Expert Perspectives on NIPT
Following screening, genetic testing can occur during pregnancy for Down syndrome, Trisomy 18, and other conditions. Two major types of genetic testing.
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
Most provincial and territorial health insurance programs cover prenatal blood screening for chromosomal anomalies (Down syndrome and Trisomy 18) and neural.
Nuchal translucency screening uses ultrasound to screen for Down syndrome, other conditions caused by an extra chromosome (trisomy 13 and 18), and congenital.
UOG Journal Club: October 2019
Presentation transcript:

Non-Invasive Prenatal Testing Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Special thanks to the Children’s Hospital of Eastern Ontario’s Prenatal Genetics Team Last updated April 2014

Disclaimer This presentation is for educational purposes only and should not be used as a substitute for clinical judgement. GEC-KO aims to aid the practicing clinician by providing informed opinions regarding genetic services that have been developed in a rigorous and evidence-based manner. Physicians must use their own clinical judgement in addition to published articles and the information presented herein. GEC-KO assumes no responsibility or liability resulting from the use of information contained herein.

Objectives Following this session the learner will be able to: Refer to their local genetics centre and/or order genetic testing appropriately for prenatal screening Discuss and address patient concerns regarding prenatal screening Facilitate patient informed decision making regarding prenatal screening options Find high quality genomics educational resources appropriate for primary care

Case 1 A 32 year old woman has had a positive Integrated Prenatal Screening Test (IPS) result for Down syndrome. She is about 17 weeks gestation. Is NIPT a good option?

Case 2 A 40 year old G1 woman is about 9 weeks gestation. She is in your office to discuss prenatal testing options in this pregnancy conceived by IVF. Is NIPT a good option?

Case 3 A 36 year old G1P0 woman is very anxious about Down syndrome in this pregnancy because she had a second cousin with Down syndrome who passed away as a child. Is NIPT a good option?

Case 4 A 29 year old patient had a nuchal translucency (NT) of 4.4mm at 12+5 weeks gestation You offered NIPT and she accepted NIPT results were normal. She is now 14+2 weeks gestation What are the next steps?

Prenatal Screening tests for: DS, T18, T13 and ONTD Recommendations: any prenatal screen offered to women who present in T1 should have DR of 75% and no more than 3% FPR, if presenting in T2 DR of 75% with no more than 5% FPR Open Neural Tube Defect (ONTD): Maternal Serum – alphafetoprotein (MSAFP) in T2 + comprehensive U/S screen at 18-20 weeks U/S for delayed ossification of fetal nasal bone – T1 (11-14 weeks) or T2 T1 DR 69% FPR depending on maternal ethnicity (9% Afro-Caribbeans, 5% Asians, 2.2% Caucasian)

What is Non-Invasive Prenatal Testing? Screening test to prenatally detect Down syndrome and other aneuploidies (extra or missing chromosomes) trisomy 21, 18, 13 trisomy of sex chromosomes (XXX, XXY, XYY) Turner syndrome (monosomy X) triploidy (extra copy of all chromosomes) Aneuploidy: refers to an abnormal chromosome number (extra or missing)

Non-Invasive Prenatal Testing (NIPT) NIPT measures circulating cell-free DNA (cfDNA) from placenta present in maternal blood Comprises ~10% of DNA in maternal blood Increases with gestational age Companies offering NIPT use various technologies to analyze cfDNA and determine chromosome quantities Performed on maternal blood sample As early as 9 weeks gestation (company specific) Dating U/S – viability, accurate GA, exclude multiples Technologies: detect higher relative amounts of DNA from an aneuploidy fetus by comparing quantity to a reference chromosome, determining if there is a normal, higher or lower than expected quantity of particular DNA sequences amplify and sequence chromosomes of interest using single-nucleotide polymorphisms (SNPs)

How good is Non-Invasive Prenatal Testing? Moving target Currently literature is primarily from companies or those holding patents Overall ranges T21 T18 T13 Specificity (%) 99-100 Sensitivity (%) 98-100 97-100 79-100 Positive Predictive Value [PPV] (%) 90-95* 84* 52* Negative Predictive Value [NPV] (%) 99.9 99 100 These numbers are in evolution Range per company - all better than current screening Pick up majority of cases but likelihood of true positive depends on frequency of condition. CONFIRM the RESULT!!!!!!! Sensitivity (also called the true positive rate,) measures the proportion of actual positives which are correctly identified as such (e.g. the percentage of sick people who are correctly identified as having the condition). Specificity measures the proportion of negatives which are correctly identified as such. (e.g. the percentage of healthy people who are correctly identified as not having the condition, sometimes called the true negative rate). the positive predictive value, or precision rate is the proportion of positive test results that are true positives NPV: the proportion of negative test results that are true negatives For IPS: the PPV is probably around 10% for T21; the detection rate approaches 90% for T21 *ASHG Oct 2013 platform presentation – data from BGI China; 63,543 pregnancies

What is the evidence for Non-Invasive Prenatal Testing (NIPT)? Studies emerging in low-risk population Performance of NIPT in a general obstetrical population False Positive Rate (FPR) for T21 and T18 combined was 0.5% vs 4.2% for standard screening Positive Predictive Value (PPV) was significantly higher than that for standard screening, for both trisomy 21 (45.5% vs. 4.2%) and trisomy 18 (40.0% vs. 8.3%) PPV - the percentage of patients with a positive test who actually have the disease NPV – the percentage of patients with a negative test who do not have the disease Specificity - ability of a test to correctly classify an individual as disease- free Sensitivity - Sensitivity is the ability of a test to correctly classify an individual as ′diseased Bianchi et al, NEJM 2014; 370:9

What is the evidence for Non-Invasive Prenatal Testing (NIPT)? 7 studies of “high risk” women High risk: Screen (IPS, FTS) positive AMA (≥35 yrs) Ultrasound findings suggestive of aneuploidy Previous pregnancy with aneuploidy

What is the evidence for Non-Invasive Prenatal Testing (NIPT)? By far most accurate performance for T21/18 Benn et al, Ultras Obstet Gynecol 2013, 42: 15-33

What do the experts say? Society of Obstetricians & Gynecologists of Canada 2013 Non-invasive prenatal testing using massive parallel sequencing of cell-free DNA to test for trisomies 21, 18, and 13 should be an option available to women at increased risk in lieu of amniocentesis. Pre-test counselling of these women should include a discussion of the limitations of non-invasive prenatal testing. Genetics Ctte Technical Update JOGC: Feb 2013

What do the experts say? Society of Obstetricians & Gynecologists of Canada 2013 No irrevocable obstetrical decision should be made in pregnancies with a positive non-invasive prenatal testing result without confirmatory invasive diagnostic testing. Genetics Ctte Technical Update JOGC: Feb 2013

Recommendations Offer all women: Prenatal screening using either FTS, IPS or MSS (SIPS or Quad) Fetal morphology scan at 18-20 weeks’ gestation

Consider discussing Non-Invasive Prenatal Testing (NIPT) as an option for women who: Are of advanced maternal age , defined as 40 years of age or older at estimated date of birth Have an abnormal multiple marker screen i.e. FTS/IPS/MSS Have fetal nuchal translucency (NT) measurement of 3.5mm or greater  Have had a previous pregnancy or child with aneuploidy Have other high risk factors: Fetal congenital anomalies on ultrasound highly suggestive of trisomy 13, 18 or 21* Soft markers on ultrasound which are highly suggestive of aneuploidy [Refer to SOGC guidelines, 2005].* At risk of carrying a male fetus with an X-linked condition (NIPT would be used for sex determination)* In Ontario, MOHLTC funding applications for the indications above marked by an asterisk (*) must be submitted by a geneticist or maternal fetal medicine (MFM) specialist. In other provinces circumstances may be different. Consult your local genetics centre or MFM specialist.

Non-Invasive Prenatal Testing (NIPT) results Results will be reported differently and may be worded as: positive or negative aneuploidy detected, no aneuploidy detected or aneuploidy suspected/borderline value high risk or low risk

Non-Invasive Prenatal Testing (NIPT) results If the result is negative, this is reassuring Your patient should still be offered: MS-AFP between 15 and 20+6/7 weeks to screen for open neural tube defect, as NIPT does not screen for this physical anomaly fetal morphology scan at 18-20 weeks’ gestation referral for genetic and/or maternal fetal medicine consultation, which may be indicated for additional counselling and testing, depending on the reason your patient qualified for NIPT (e.g. increased NT, other soft markers, congenital anomalies)

Non-Invasive Prenatal Testing (NIPT) results If the result is positive: Genetic counselling Confirmation by diagnostic testing No irrevocable obstetrical decisions should be made in pregnancies with abnormal NIPT results without confirmatory invasive testing (CVS or amniocentesis) - SOGC

Benefits of Non-Invasive Prenatal Testing (NIPT) Fewer women having diagnostic tests with associated risk of pregnancy loss Early test result (drawn at ≥ 9-10 weeks at earliest) No risk of miscarriage Detects the most common chromosomal aneuploidies Higher detection rates and lower false positive rates than IPS or MSS

Limitations of Non-Invasive Prenatal Testing (NIPT) NIPT cannot: Detect chromosome differences other than aneuploidy of chromosomes 13, 18, 21, X and Y some companies are now adding screening for other trisomies and certain microdeletion syndromes Completely rule out aneuploidy Detect single gene conditions Detect congenital anomalies Failed results 6.1% untested for insufficient sample quality 2% no result after testing (rarely happens with conventional screening) cfDNA decreases with increased maternal BMI, twin pregnancies and where trisomy 18 and 13 are present Limited data on performance in IVF pregnancies

Limitations of Non-Invasive Prenatal Testing: Confined placental mosaicism False positives (and negatives) are possible Confined placental mosaicism Trisomy 13 and 18  lower placenta volume Rava RP et al. (2014). Clinical Chemistry, 60, 243-50. Wegrzyn et al. (2005). Ultrasound in Obstetrics & Gynecology, 26, 28-32.

Non-Invasive Prenatal Testing (NIPT) Landscape Increasing demand from women Increasing uptake in most (urban) centres 3 separate companies, 3 separate technologies Has NIPT become “standard of care”? Costs between $795 and $1200 8-10 days for result

11 to 14 week scan has value to pregnancy care Where does Non-Invasive Prenatal Testing (NIPT) fit with respect to the 11 to 14 wk scan? 11 to 14 week scan has value to pregnancy care Raised NT may suggest other chromosomal, genetic and structural disorders Accurate dating/establishment of live fetus Multiples/chorionicity affects management Detects structural abnormalities

Non-Invasive Prenatal Testing (NIPT) and counselling Pre- and post-test counselling is important Consult genetics if unsure Refer for genetic counselling when appropriate Company websites: Harmony Prenatal Test™ by Ariosa Diagnostics through Gamma-Dynacare Panorama™ by Natera through Lifelabs Verifi® Prenatal Test by Verinata

Ordering Non-Invasive Prenatal Testing (NIPT) In Ontario, to order NIPT, first determine your patient’s funding eligibility by looking at the MOHLTC checklist, then: Complete the checklist and pages 2 and 4 of the MOHLTC out-of-country testing prior approval form Download and complete the requisition from the NIPT company of your and your patient’s choice Selection may be based on the patient’s personal research and preference, your experience with a particular company, ease of access to a blood draw location Send all three completed forms to the fax number 613 536-3181 or 1 866 221-3536 and be sure to indicate the patient is pregnant so approval can be prioritized accordingly Once approval has been received, give the patient the approval letter and the NIPT requisition and she can then have her blood drawn

Case 1 A 36 year old woman has had a positive Integrated Prenatal Screening Test (IPS) result for Down syndrome. She is about 17 weeks gestation. Is NIPT a good option?

Yes But consider: She is eligible for NIPT with MOH funding More rapid result from amniocentesis What is her IPS risk? 1 in 2 versus 1 in 120 She is at 17 weeks gestational age If NIPT is positive, guidelines recommend confirmatory diagnostic testing by amniocentesis – delays timing for diagnosis In the event of an abnormal result, is termination of pregnancy an option for the couple?

Case 2 A 40 year old G1 woman is about 9 weeks gestation. She is in your office to discuss prenatal testing options in this pregnancy conceived by IVF. Is NIPT a good option?

Yes Advanced maternal age (greater than 40 years at EDB) is an appropriate indication for NIPT Covered by MOH funding Better screen than IPS Earlier result Decreased chance with NIPT that patient would receive screen positive result

Case 3 A 36 year old G1P0 woman is very anxious about Down syndrome in this pregnancy because she had a second cousin with Down syndrome who passed away as a child. Is NIPT a good option?

Case 3 She does not meet MOH criteria for coverage of NIPT You can reassure her that having a second cousin with Down syndrome does not increase her risk to have an affected child If she is very anxious, you can proceed with NIPT and she can pay out of pocket If the patient herself had a previous affected pregnancy then she would be eligible for MOH funded NIPT 1a 1b 2a 2b 3b 3a 4a 4b 4a has Down syndrome 4b and 4a are second cousins – 5th degree relatives P

Case 4 A 29 year old patient had an NT of 4.4mm at 12+5 weeks gestation You offered NIPT and she accepted NIPT results were normal. She is now 14+2 weeks gestation What are the next steps?

Genetic counselling is recommended Patient likely to be offered: Chromosomal microarray Genetic testing for other single gene conditions Level II ultrasound Fetal echocardiogram

Prenatal Screening Summary Offer all pregnant women, regardless of age: PN screening for fetal aneuploidy (trisomy 13, 18, 21) through FTS, IPS, SIPS or Quad screening Second trimester ultrasound for dating, assessment of fetal anatomy and detection of multiples Maternal age should not be used as a basis for recommending invasive testing when non-invasive PN screening is available Non-Invasive Prenatal Testing (NIPT) Consider offering NIPT to high risk women Consider NIPT as a screen of higher sensitivity if your patient is willing to pay for the test Best for Down syndrome (trisomy 21) (but can be wrong!) so far, others not as good (T13 and sex chromosomes) Effectively sampling the placenta (not fetal cells directly) It is not a diagnostic test Not an all purpose genetic test, only gives info on specific chromosomes, and so not indicated in all circumstances NIPT is ok for T18, not as good as T21 but better than T13 and the sex chromosomes

Don’t forget Take a family history to identify familial and/or ethnicity-specific disorders and screen accordingly Consider consanguinity and screen and test accordingly Refer or consult genetics when in doubt

Useful Genetics Resources GEC-KO website: Genetics Education www.geneticseducation.ca NIPT fact sheets: http://www.mountsinai.on.ca/care/family-medicine-genetics-program/prenatal Prenatal Screening Ontario Website http://www.prenatalscreeningontario.ca/ Society of Obstetricians and Gynaecologists of Canada (SOGC) national clinical guidelines in prenatal genetics visit http://sogc.org/clinical-practice-guidelines/ and scroll down to Genetics.